| Laura Jean Burnside-mcelligott, | |
|
1890 Waite St, Ste 1, North Bend, OR 97459-1229 | |
| (541) 756-6232 | |
| (541) 756-6234 |
| Full Name | Laura Jean Burnside-mcelligott |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 1890 Waite St, North Bend, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477718419 | NPI | - | NPPES |
| 213342 | Medicaid | OR | |
| 500617181 | Medicaid | OR | |
| R163722 | Other | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 081046951RN (Oregon) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 200850064NP FNP-PP (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Laura Jean Burnside-mcelligott, 1890 Waite St, Ste 1, North Bend, OR 97459-1229 Ph: (541) 756-6232 | Laura Jean Burnside-mcelligott, 1890 Waite St, Ste 1, North Bend, OR 97459-1229 Ph: (541) 756-6232 |
News Archive
An international team of scientists has identified variants of the gene EBF3 causing a developmental disorder with features in common with autism.
Harbor BioSciences, Inc. today announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286). The patent claims cover compounds including Triolex and formulations that contain the drug or the other claimed compounds.
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
AstraZeneca and MedImmune, the company's global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
RHEI Pharmaceuticals, Inc. has announced that the final clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system, has been initiated in China.
› Verified 3 days ago
Shu-wen Cheng, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1890 Waite St, North Bend, OR 97459 Phone: 541-756-6232 | |
Dawn Mcelhaney, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2191 Marion St, Va-cboc, North Bend, OR 97459 Phone: 541-756-8002 Fax: 541-765-7503 | |
Dr. Pei J Harris, DNP, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1430 Scott Ln, North Bend, OR 97459 Phone: 541-283-5662 | |
Sophia B Cording, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1975 Mcpherson St, Suite 2, North Bend, OR 97459 Phone: 541-756-2020 Fax: 541-756-8982 | |
Ms. Challis Annette Casebolt, WHC NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1975 Mcpherson, #1, North Bend, OR 97459 Phone: 541-756-2020 Fax: 541-756-5828 | |
Ya-chi Claire Chang, Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1229 1890 Waite St #1, North Bend, OR 97459 Phone: 713-454-2261 | |
Mrs. Hedian C Swanson, MSN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2191 Marion St, North Bend, OR 97459 Phone: 541-756-8002 Fax: 541-756-7503 |